Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody

BACKGROUND: Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity. Some real‐world efficacy and safety studies of anti‐PD‐1 antibody have been previously reported. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuya, Naoki, Nishino, Makoto, Wakuda, Kazushige, Ikeda, Satoshi, Sato, Takashi, Ushio, Ryota, Tanzawa, Shigeru, Sata, Masafumi, Ito, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919123/
https://www.ncbi.nlm.nih.gov/pubmed/33448648
http://dx.doi.org/10.1111/1759-7714.13824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919123/
https://www.ncbi.nlm.nih.gov/pubmed/33448648
http://dx.doi.org/10.1111/1759-7714.13824

Ejemplares similares